- McGill University, Neurology Department
- Dystroglycan function and dysfunction in the fly CNS
- $76,145 (2006 through 2007)
- Co-Investigator: Dr. Yong Rao
- Understanding how dystroglycan operates in the nervous system will be important in developing strategies to help mitigate the impact of mutations that affect dystroglycan function in the brain, leading to cognitive problems associated with dystroglycan mediated muscle diseases
- University of Toronto
- Analysis of transmitter release mechanisms
- $156,834 (2006 through 2007)
- Studies into the mechanisms of this presynaptic differentiation may allow future development of therapeutics that can be selectively aimed at synaptic enhancement, thereby allowing for faster recovery from injury to muscles
- McGill University
- The role of protein chaperones and proteasomemediated proteolysis in the pathogenesis of motor neuron diseases
- $133,077 (2006 through 2007)
- The hypothesis is that the protein chaperoning and ubiquitin/proteasome systems play an important role in regulating the assembly, and maintaining the stability, of neurofilament networks. If HSPs are important in the integrity of these neurofilament networks, then an increase in the activity (upregulation) of HSPs may protect neurons from disease mechanisms
- McMaster University
- Mechanism of sensory protection of denervated muscle
- Co-Investigators: Dr. James Bain and Dr. Jan Batt
- $149,033 (2006 through 2007)
- Such factors are potential targets for therapeutic intervention. This work also will advance the clinical use of sensory protection for the treatment of prolonged muscle denervation due to injury or disease
- McGill University
- Development of an integrating adenoviral vector for gene therapy of Duchenne muscular dystrophy
- $278,784 (2006 through 2009)
- Co-Investigator: Dr. Bernard Massie
- making muscles
- The experiments should lead in the development of an invaluable vector that may be used for treating DMD using a cell and/or gene therapy approach. For both types of experiments (gene and cell therapy) duration of dystrophin expression and beneficial effects will be evaluated
- University of Waterloo
- Molecular therapies for dystrophin deficiency
- $281,304 (2006 through 2009)
- Such knowledge is critical for understanding and ultimately intervening to ameliorate the effects of abnormal protein aggregation in ALS
- University of Toronto
- Peripherin abnormalities in amyotrophic lateral sclerosis
- $350,306 (2006 through 2009)
- This research will further characterize and describe peripherin forms and their creation as a means to understanding the mechanisms that cause ALS
- Ottawa Health Research Institute
- Satellite stem cells from skeletal muscle for the treatment of neuromuscular disease
- $470,554 (2006 through 2011)
- This research should provide important new information into the biology of muscle regeneration and open new avenues for therapeutic intervention for the treatment of neuromuscular disease
- Laval University
- Development of immunological tolerance in monkeys for therapy for muscular dystrophies based on cell transplantation
- $386,338 (2006 through 2009)
- This protocol to induce immunological tolerance may also be applied to permit the successful transplantation of other types of cells and of organs
